From a lack of effective endpoints to measure clinical success to a limited number of available trial participants, biopharma companies face challenges in rare disease drug development.
The Home of the Life Sciences Industry
Genentech has partnered with Jemincare to develop and commercialize an asset that may provide new treatment options for people with advanced-stage prostate cancer.
More Top Stories
- Curis Stock Soars after FDA Lifts Partial Hold on Lymphoma Trial
- Jazz Takes Groundbreaking Epilepsy Drug into Kids in Phase III Trial
- bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene ...
- Paxlovid Rebound: RWE Analysis and Alternative Therapies in Develop...
- Bavarian Nordic Seeks Help as Monkeypox Vaccine Supply Line Crumbles